FDA approved an at-home induction option for risankizumab-rzaa in adults with moderate-to-severe Crohn's disease, based on the phase 3 AFFIRM trial.
Blog|Articles|July 26, 2018
Editorial Board
Advertisement
Subscription Support
Contact MMHInfo@mmhgroup.com for subscription-related questions only.
Press Releases and News Announcements
Send press releases and other announcements relevant to the pharma c-suite to pharmexec@mjhlifesciences.com.
Submit Article and/or Podcast Proposals
Use
Editorial Staff (US)
Assistant Managing Editor
mhollan@mjhlifesciences.com
Group Managing Editor
mchristel@mjhlifesciences.com
Assistant Editor
njacobus@mjhlifesciences.com
Custom Projects Staff
Vice President, Content & Special Projects
Jeanne Linke
Managing Editor
Megan Manzano
Senior Editor
Shannon Stolz
Senior Editor
Additional Information
Advertisement
Related to this article
Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and Zymeworks’ licensing deal with Roche, and Incubate’s John Stanford on why MFN is an offer pharma can’t refuse.
Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
Gilead agrees to acquire an oral IL-23R inhibitor from PepStar, while Zymeworks licenses its DLL3-targeting T cell engager ZW209 to Roche.
Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.
Alcon is acquiring Neurotech Pharmaceuticals to add the only FDA-approved MacTel cell therapy to its retina portfolio, while AI Proteins has enters a collaboration with Astellas to design novel miniprotein therapeutics.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche
2
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
3
FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease
4
MFN Is an Offer Pharma Can’t Refuse
5